Physician profile
Mikhail Meyerovich
NPI 1073506952
$2,154.67
in general payments reported to CMS, 2019-2025
16 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,194 · 2020: $213 · 2023: $275 · 2024: $223 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.96 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $422.82 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $236.02 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $168.27 | 2019 | |
| Vanda Pharmaceuticals INC. | $118.74 | 2019-2020 | |
| Allergan, INC. | $112.62 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $109.96 | 2019-2020 | |
| Lundbeck LLC | $108.91 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $88.35 | 2019-2024 | Rexulti |
| Bausch Health US, LLC | $88.17 | 2023 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $41.57 | 2019 | |
| Shire North American Group INC | $25.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.18 | 2019 | |
| Jazz Pharmaceuticals INC. | $23.82 | 2019 | |
| Idorsia Pharmaceuticals US INC | $23.35 | 2023 | Quviviq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $22.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Meyerovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.